Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-respondersChristian Gytz Ammitzbøll, Anne Troldborg, Christian Erikstrup et al.|Lara D. Veeken|2022Cited by 16
Molecular mechanisms underlying thrombosis in systemic lupus erythematosus – A Systematic reviewMads Lamm Larsen, Anne Troldborg, Ellen‐Margrethe Hauge et al.|Seminars in Arthritis and Rheumatism|2025Cited by 9
Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical ImplicationsMads Lamm Larsen, Mads Nyhuus Bendix Rasch, Morten Kelder Skouboe et al.|American Journal of Case Reports|2024Cited by 9
Differentiating between activation via the lectin or the classical complement pathway in patients with systemic lupus erythematosusMads Lamm Larsen, Steffen Thiel, Anne Troldborg et al.|Clinical & Experimental Immunology|2023Cited by 5
COVID‐19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post‐Pandemic Concerns About the Impact of RituximabChristian Gytz Ammitzbøll, Anne Troldborg, Marianne Kragh Thomsen et al.|ACR Open Rheumatology|2024Cited by 5